• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

    3/27/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GANX alert in real time by email

    BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update.

    "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO of Gain. "Building upon this momentum in 2025, we have recently initiated dosing in our Phase 1b trial of GT-02287 and look forward to sharing results from a first analysis of the study anticipated for the end of the second quarter of 2025. We believe the observations from this analysis will mark a significant value inflection point for the GT-02287 program and importantly, inform the planning of our Phase 2 study during the second half of 2025. At the same time, we are working towards expanding GT-02287 clinical development to the U.S. and continue to have productive dialogue with the FDA. We look forward to providing continued updates on our progress as we aim to achieve these milestones throughout the year."

    Fourth Quarter 2024 and Recent Corporate Highlights

    Pipeline Updates

    • First participant dosed in the Phase 1b trial of GT-02287 in Parkinson's disease. First analysis is anticipated at the end of the second quarter 2025.
    • Presented new clinical data from a Phase 1 study of GT-02287 in healthy volunteers that demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement with a statistically significant >50% increase in glucocerebrosidase (GCase) activity among those receiving GT-02287 at clinically relevant doses during the Michael J. Fox Foundation's 16th Annual Parkinson's Disease Therapeutics Conference in October 2024 in New York, NY.
    • Presented preclinical data elucidating a broader impact on the biology of Parkinson's disease than was previously understood to be associated with GT-02287 stabilization and modulation of GCase, including important observations of its role in supporting mitochondrial health at the Society for Neuroscience 2024 conference in October 2024 in Chicago, IL.
    • Presented a poster highlighting the use of the Company's Magellan™ drug discovery platform to identify allosteric inhibitors targeting discoidin domain receptor 2 at the 36th EORTC-NCI-AACR Symposium in October 2024 in Barcelona, Spain.

    Corporate Updates

    • Gene Mack was appointed President and Chief Executive Officer effective January 6, 2025. Gianluca Fuggetta assumed the role of Senior Vice President Finance and Principal Financial Officer.
    • Announced formation of Clinical Advisory Board composed of leading experts in Parkinson's disease to support the advancement of GT-02287 through late-stage clinical development.
    • Commenced pre-Investigational New Drug (IND) engagement with U.S. Food and Drug Administration (FDA) in preparation for expansion of GT-02287 Phase 2 clinical development to include the United States.

    Upcoming Anticipated Milestones

    • First analysis from Phase 1b trial evaluating GT-02287 in Parkinson's disease patients expected at the end of Q2 2025.
    • IND submission to FDA expected by year end 2025.

    Year End 2024 Financial Results

    Research and development (R&D) expenses decreased by $0.7 million to $10.8 million for year ended December 31, 2024, as compared to $11.5 million for the year ended December 31, 2023. The decrease in research and development expenses was primarily related to higher recognition of research grant income principally comprised of a tax credit for eligible research and development expenses in Australia. These increases were partially offset by higher costs during 2024 associated with the Phase 1 clinical trial of the Company's lead program compound GT-02287 for the treatment of Parkinson's disease.

    General and administrative (G&A) expenses decreased by $1.2 million to $9.6 million for the year ended December 31, 2024, as compared to $10.8 million for the year ended December 31, 2023. The decrease in general and administrative expenses was primarily attributable to lower personnel and stock-based compensation costs.

    Net loss for the year ended December 31, 2024, was $20.4 million, or $0.89 per share, basic and diluted, compared to $22.3 million, or $1.71 per share, basic and diluted, for the year ended December 31, 2023. The decrease in net loss for 2024 compared to 2023 was primarily

    attributable to decreases in R&D expenses of $0.7 million and G&A expenses of $1.2 million.

    Cash, cash equivalent and marketable securities were $10.4 million as of December 31, 2024, compared to $16.8 million as of December 31, 2023.

    About GT-02287

    Gain Therapeutics' lead drug candidate, GT-02287, is in clinical development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation. The orally administered, brain-penetrant small molecule is an allosteric enzyme modulator that restores the function of the lysosomal enzyme glucocerebrosidase (GCase) which becomes misfolded and impaired due to mutations in the GBA1 gene, the most common genetic abnormality associated with PD, or other age-related stress factors. In preclinical models of PD, GT-02287 restored GCase enzymatic function, reduced aggregated α-synuclein, neuroinflammation and neuronal death, and improved motor function and cognitive performance. Additionally, GT-02287 significantly reduced plasma neurofilament light chain (NfL) levels, an emerging biomarker of neurodegeneration.

    Compelling preclinical data in models of both GBA1-PD and idiopathic PD, demonstrating a disease-modifying effect after administration of GT-02287, suggest that GT-02287 may have the potential to slow or stop the progression of Parkinson's disease.

    Gain's lead program in Parkinson's disease has been awarded funding support early in its development from The Michael J. Fox Foundation for Parkinson's Research (MJFF) and The Silverstein Foundation for Parkinson's with GBA, as well as from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.

    About Gain Therapeutics, Inc.

    Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate, GT-02287 is currently being evaluated for the treatment of Parkinson's disease with or without a GBA1 mutation. Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma exposure in the projected therapeutic range, CNS exposure, and target engagement and modulation of GCase enzyme.

    Gain's unique approach enables the discovery of novel, allosteric small molecule modulators that can restore or disrupt protein function. Deploying its highly advanced Magellan™ platform, Gain is accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders including neurodegenerative diseases, rare genetic disorders and oncology.

    Forward-Looking Statements

    This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, statements regarding: the development of the Company's current or future product candidates including GT-02287; expectations regarding the timing of results from a Phase 1b clinical study for GT-02287; expectations regarding the timing of patient enrollment for a Phase 1b clinical study for GT-02287; the timing of any submissions to the FDA or other regulatory bodies and agencies; and the potential therapeutic and clinical benefits of the Company's product candidates. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to the Company's Form 10-K for the year ended December 31, 2024. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

    Investor Contacts:

    Apaar Jammu and Chuck Padala

    [email protected]

    [email protected]

    Media Contacts:

    Russo Partners

    Nic Johnson and Elio Ambrosio

    [email protected]

    [email protected]

    (760) 846-9256

    Gain Therapeutics, Inc

    Consolidated Statements of Operations
           
      Year Ended December 31,
      2024  2023 
    Revenues:      
    Collaboration revenues $—  $55,180 
    Other income  —   — 
    Total revenues  —   55,180 
           
    Operating expenses:      
    Research and development  (10,791,058)  (11,520,613)
    General and administrative  (9,559,534)  (10,787,700)
    Total operating expenses  (20,350,592)  (22,308,313)
           
    Loss from operations  (20,350,592)  (22,253,133)
           
    Other income (expense):      
    Interest income, net  357,096   494,234 
    Foreign exchange gain (loss), net  119,120   (429,346)
    Loss before income tax  (19,874,376)  (22,188,245)
           
    Income tax  (536,815)  (79,275)
           
    Net loss $(20,411,191) $(22,267,520)
           
    Net loss per shares:      
    Net loss per share attributable to common stockholders - basic and diluted $(0.89) $(1.71)
    Weighted average common stock - basic and diluted  22,881,415   13,011,361 



    Gain Therapeutics, Inc

    Consolidated Balance Sheets
            
       December 31, December 31,
       2024  2023 
    Assets       
    Current assets:       
    Cash and cash equivalents  $10,385,863  $11,794,949 
    Marketable securities - current   —   4,999,704 
    Tax credits   271,079   242,577 
    Prepaid expenses and other current assets   945,536   741,638 
    Total current assets   11,602,478   17,778,868 
            
    Noncurrent assets:       
    Property and equipment, net   103,619   125,962 
    Internal-use software   134,268   193,375 
    Operating lease - right-of-use assets   219,715   459,215 
    Restricted cash   31,695   34,021 
    Long-term deposits and other noncurrent assets   32,109   17,890 
    Total noncurrent assets   521,406   830,463 
    Total assets  $12,123,884  $18,609,331 
            
    Liabilities and stockholder's equity       
    Current liabilities:       
    Accounts payable  $946,259  $1,318,965 
    Operating lease liability - current   160,913   229,693 
    Other current liabilities   2,441,761   2,160,366 
    Deferred grant income - current   252,211   1,122,138 
    Loans - current   110,177   118,797 
    Total current liabilities   3,911,321   4,949,959 
            
    Noncurrent liabilities:       
    Defined benefit pension plan   443,623   307,454 
    Operating lease liability - noncurrent   53,598   229,855 
    Deferred grant income - noncurrent   47,441   94,786 
    Loans - noncurrent   328,327   449,053 
    Total noncurrent liabilities   872,989   1,081,148 
    Total liabilities  $4,784,310  $6,031,107 
            
    Stockholders' equity       
    Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of December 31, 2024 and 2023  $—  $— 
    Common stock, $0.0001 par value: 50,000,000 shares authorized; 27,132,588 and 16,206,680 shares issued and outstanding as of December 31, 2024 and 2023, respectively   2,713   1,621 
    Additional paid-in capital   88,779,318   73,113,079 
    Accumulated other comprehensive (loss) income   (247,549)  247,241 
    Accumulated deficit   (60,783,717)  (38,516,197)
    Loss of the period   (20,411,191)  (22,267,520)
    Total stockholders' equity   7,339,574   12,578,224 
    Total liabilities and stockholders' equity  $12,123,884  $18,609,331 


    Primary Logo

    Get the next $GANX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $GANX

    DatePrice TargetRatingAnalyst
    3/7/2025$12.00Sector Outperform
    Scotiabank
    12/6/2024$7.00Buy
    ROTH MKM
    8/14/2024$8.00Outperform
    Oppenheimer
    11/3/2021$21.00Buy
    B. Riley Securities
    More analyst ratings

    $GANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CFO and Interim CEO Mack Gene bought $14,544 worth of shares (14,400 units at $1.01) (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      8/12/24 5:23:31 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Executive Chairman Islam Khalid bought $49,940 worth of shares (50,000 units at $1.00) (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      8/12/24 5:23:30 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Richman Eric I bought $20,670 worth of shares (17,000 units at $1.22), increasing direct ownership by 6% to 289,629 units (SEC Form 4)

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      7/1/24 5:00:27 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Islam Khalid

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:23 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Richman Eric I

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:19 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nicaise Claude

      4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

      6/25/25 5:30:22 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    SEC Filings

    See more
    • Gain Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

      6/30/25 4:30:29 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

      6/24/25 5:09:42 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Gain Therapeutics Inc.

      S-3 - Gain Therapeutics, Inc. (0001819411) (Filer)

      5/28/25 5:01:17 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Scotiabank initiated coverage on Gain Therapeutics with a new price target

      Scotiabank initiated coverage of Gain Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

      3/7/25 8:20:06 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH MKM initiated coverage on Gain Therapeutics with a new price target

      ROTH MKM initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $7.00

      12/6/24 7:48:38 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer resumed coverage on Gain Therapeutics with a new price target

      Oppenheimer resumed coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $8.00

      8/14/24 7:36:01 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 Mutation

      As of June 30th, 16 participants have enrolled in the Phase 1b, ahead of the original goal of at least 15 total participants by 3Q 2025 Analysis of 90-day biomarker activity from cerebrospinal fluid (CSF) in all participants currently enrolled is now expected to also track earlier; available in 4Q 2025 instead of 1Q 2026 Gain will continue screening patients for enrollment through July 31st, 2025, at the request of clinical investigators and additional participants who wish to gain access to the study The independent data monitoring committee (DMC) met recently and recommended to continue the study with no changes in dose level; no serious treatment emergent adverse events (TEAEs) h

      6/30/25 4:05:00 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics to Participate in Upcoming Investor Conferences

      BETHESDA, Md., June 10, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, President and CEO of Gain, will present at two upcoming investor conferences: H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference Tuesday, June 17, at 7:00 a.m. EST: Gene Mack will participate in a virtual fireside chat with Raghuram Selvaraju, Ph.D. BIO 2025 Wednesday, June 18, at 1:45 p.m. EST: Gene Mack will give a corporate presentation in Room 153C at the Boston Convention and Exhibition

      6/10/25 8:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

      BETHESDA, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced an oral presentation at the GBA1 Meeting 2025, being held June 5th-7th in Montreal, Canada. Details of the oral presentation are as follows: Date: Thursday, June 5, 2025 Time: 11:20 p.m. EST Presenter: Jonas Hannestad, M.D., Ph.D., Chief Medical Officer, Gain Therapeutics About Gain Therapeutics, Inc.Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generatio

      5/29/25 8:45:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Financials

    Live finance-specific insights

    See more
    • Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

      BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

      5/14/25 7:30:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

      BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

      3/27/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

      BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. "The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson's disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson's Disease and Movement

      11/14/24 4:05:00 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Gain Therapeutics Inc.

      SC 13G/A - Gain Therapeutics, Inc. (0001819411) (Subject)

      3/29/21 11:59:04 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GANX
    Leadership Updates

    Live Leadership Updates

    See more
    • Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

      Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company's Chief Financial Officer since April 2024 and interim Chief Executive Officer since June 2024, has been appointed President and Chief Executive Officer, effective January 6, 2025. Mr. Mack has also been appointed as a me

      1/7/25 7:00:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

      Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Finan

      6/27/24 4:08:08 PM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

      BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record of successful financing, M&A and other strategic transactions combined with his scientific background and career as an equity research analyst ideally complement our executive man

      4/8/24 9:25:00 AM ET
      $GANX
      Biotechnology: Pharmaceutical Preparations
      Health Care